NEUBASE THERAPEUTICS INC (NBSE) Stock Fundamental Analysis

NASDAQ:NBSE • US64132K2015

0.378 USD
-0.01 (-3.2%)
At close: May 10, 2024
0.42 USD
+0.04 (+11.11%)
After Hours: 5/10/2024, 8:08:45 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NBSE. NBSE was compared to 521 industry peers in the Biotechnology industry. While NBSE seems to be doing ok healthwise, there are quite some concerns on its profitability. NBSE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • NBSE had negative earnings in the past year.
  • In the past year NBSE had a positive cash flow from operations.
  • In the past 5 years NBSE always reported negative net income.
  • NBSE had a negative operating cash flow in each of the past 5 years.
NBSE Yearly Net Income VS EBIT VS OCF VS FCFNBSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

  • NBSE has a Return On Assets of -73.74%. This is in the lower half of the industry: NBSE underperforms 69.40% of its industry peers.
  • NBSE has a Return On Equity of -150.22%. This is in the lower half of the industry: NBSE underperforms 65.98% of its industry peers.
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROIC N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
NBSE Yearly ROA, ROE, ROICNBSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

  • NBSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBSE Yearly Profit, Operating, Gross MarginsNBSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, NBSE has more shares outstanding
  • Compared to 1 year ago, NBSE has an improved debt to assets ratio.
NBSE Yearly Shares OutstandingNBSE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
NBSE Yearly Total Debt VS Total AssetsNBSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -10.48, we must say that NBSE is in the distress zone and has some risk of bankruptcy.
  • NBSE has a worse Altman-Z score (-10.48) than 78.97% of its industry peers.
  • NBSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -10.48
ROIC/WACCN/A
WACCN/A
NBSE Yearly LT Debt VS Equity VS FCFNBSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

  • NBSE has a Current Ratio of 2.87. This indicates that NBSE is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of NBSE (2.87) is worse than 68.03% of its industry peers.
  • A Quick Ratio of 2.87 indicates that NBSE has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.87, NBSE is doing worse than 66.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.87
NBSE Yearly Current Assets VS Current LiabilitesNBSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 55.05% over the past year.
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.88% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NBSE Yearly EPS VS EstimatesNBSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • NBSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NBSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBSE Price Earnings VS Forward Price EarningsNBSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, NBSE is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 0.1
EV/EBITDA N/A
NBSE Per share dataNBSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

  • NBSE's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.21%
EPS Next 3Y21.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for NBSE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUBASE THERAPEUTICS INC

NASDAQ:NBSE (5/10/2024, 8:08:45 PM)

After market: 0.42 +0.04 (+11.11%)

0.378

-0.01 (-3.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13
Earnings (Next)08-12
Inst Owners3.64%
Inst Owner Change0%
Ins Owners12.28%
Ins Owner Change0%
Market Cap1.42M
Revenue(TTM)N/A
Net Income(TTM)-13.73M
Analysts43.33
Price Target142.8 (37677.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.15%
Min EPS beat(2)-2.3%
Max EPS beat(2)0%
EPS beat(4)2
Avg EPS beat(4)10.77%
Min EPS beat(4)-2.3%
Max EPS beat(4)30.42%
EPS beat(8)4
Avg EPS beat(8)4.45%
EPS beat(12)6
Avg EPS beat(12)1.88%
EPS beat(16)8
Avg EPS beat(16)-38.03%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 0.1
P/OCF 0.1
P/B 0.16
P/tB 0.16
EV/EBITDA N/A
EPS(TTM)-7.3
EYN/A
EPS(NY)-9.18
Fwd EYN/A
FCF(TTM)3.9
FCFY1032.8%
OCF(TTM)3.79
OCFY1003.88%
SpS0
BVpS2.44
TBVpS2.44
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.74%
ROE -150.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-64.47%
ROA(5y)-103.16%
ROE(3y)-82.74%
ROE(5y)-126.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr -683.33%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.87
Altman-Z -10.48
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)226.06%
Cap/Depr(5y)214.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.25%
EPS Next Y-25.75%
EPS Next 2Y-26.21%
EPS Next 3Y21.21%
EPS Next 5Y14.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y59.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y213.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y219.18%
OCF growth 3YN/A
OCF growth 5YN/A

NEUBASE THERAPEUTICS INC / NBSE FAQ

What is the ChartMill fundamental rating of NEUBASE THERAPEUTICS INC (NBSE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NBSE.


Can you provide the valuation status for NEUBASE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 2 / 10 to NEUBASE THERAPEUTICS INC (NBSE). This can be considered as Overvalued.


Can you provide the profitability details for NEUBASE THERAPEUTICS INC?

NEUBASE THERAPEUTICS INC (NBSE) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for NBSE stock?

The Earnings per Share (EPS) of NEUBASE THERAPEUTICS INC (NBSE) is expected to decline by -25.75% in the next year.